Treon, Steven P.

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood

Multiple Myeloma Research and TreatmentsCell death mechanisms and regulation

Cited by 669

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader

Huang, H.-T., Dobrovolsky, D., Paulk, J., Yang, G., Weisberg, E. L., Doctor, Z. M., Buckley, D. L., Cho, J.-H., Ko, E., Jang, J., et al. (2018) · Cell Chemical Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 437

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., et al. (2017) · Journal of the National Comprehensive Cancer Network

Multiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, Outcomes

Cited by 279

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer

Dobrovolsky, D., Wang, E. S., Morrow, S., Leahy, C., Faust, T., Nowak, R. P., Donovan, K. A., Yang, G., Li, Z., Fischer, E. S., et al. (2019) · Blood

Protein Degradation and InhibitorsChronic Lymphocytic Leukemia Research

Cited by 169

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Yang, G., Buhrlage, S. J., Tan, L., Liu, X., Chen, J., Xu, L., Tsakmaklis, N., Chen, J. G., Patterson, C. J., Brown, J. R., et al. (2016) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 135

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism

Chen, J. G., Liu, X., Munshi, M., Xu, L., Tsakmaklis, N., Demos, M. G., Kofides, A., Guerrera, M. L., Chan, G. G., Patterson, C. J., et al. (2018) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 88

Proteomic analysis of Waldenstrom macroglobulinemia

Hatjiharissi, E., Ngo, H., Leontovich, A. A., Leleu, X., Timm, M., Melhem, M., George, D., Lu, G., Ghobrial, J., Alsayed, Y., et al. (2007) · Cancer Research

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 61

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status

Cea, M., Cagnetta, A., Acharya, C., Acharya, P., Tai, Y.-T., Yang, C., Lovera, D., Soncini, D., Miglino, M., Fraternali-Orcioni, G., et al. (2016) · Clinical Cancer Research

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 28

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Bazarbachi, A. H., Avet-Loiseau, H., Szalat, R., Samur, A. A., Hunter, Z., Shammas, M., Corre, J., Fulciniti, M., Anderson, K. C., Parmigiani, G., et al. (2021) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 21